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ABSTRACT 
The aim of this work is to compare Bayesian Inference methods with commonly used non-linear 
regression (NR) algorithms for estimating pharmacokinetics in Dynamic Contrast Enhanced 
Magnetic Resonance Imaging (DCE-MRI). The algorithms are compared in terms of accuracy, 
and reproducibility under different initialization settings. Further it is investigated how a more 
robust estimation of pharmacokinetics affects cancer diagnosis. The derived pharmacokinetics 
from the Bayesian inference algorithm were validated against NR algorithms (i.e. Levenberg-
Marquardt, simplex) in terms of accuracy on a digital DCE phantom and in terms of goodness-
of-fit (Kolmogorov-Smirnov test) on ROI-based concentration time courses from two different 
patient cohorts. The first cohort consisted of 76 men, 20 of whom had significant peripheral zone 
prostate cancer (any cancer-core-length (CCL) with Gleason>3+3 or any-grade with 
CCL>=4mm) following transperineal template prostate mapping biopsy. The second cohort 
consisted of 9 healthy volunteers and 24 patients with head and neck squamous cell carcinoma. 
The diagnostic ability of the derived pharmacokinetics was assessed with receiver operating 
characteristic area under curve (ROC AUC) analysis. The Bayesian inference algorithm 
accurately recovered the ground-truth pharmacokinetics for the digital DCE phantom consistently 
improving the Structural Similarity Index (SSIM) across the 50 different initializations compared 
to NR. For optimized initialization, Bayesian inference did not improve significantly the fitting 
accuracy on both patient cohorts, and it only significantly improved the ve ROC AUC on the HN 
population from ROC AUC=0.56 for the simplex to ROC AUC=0.76.  For both cohorts, the 
values and the diagnostic ability of pharmacokinetic parameters estimated with Bayesian 
Inference weren’t affected by their initialization. To conclude, the Bayesian inference led to a 
more accurate and reproducible quantification of pharmacokinetic parameters in DCE-MRI, 
improving their ROC-AUC and decreasing their dependence on initialization settings. 
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1. Introduction 
 Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) is influenced by 
the micro-vascular characteristics of tissue, such as blood flow/volume, surface 
area/permeability of vessel walls, and micro-vascular density. These characteristics are 
associated with the expression of potent cytokines (such as the vascular endothelial growth 
factor) that support the development of tumor vessels. This makes DCE-MRI a valuable 
diagnostic tool in oncology. The purpose of this study is to investigate whether accurate 
quantification of pharmacokinetic parameters using the proposed Bayesian Inference algorithm 
can improve cancer diagnosis compared to non-linear regression fitting algorithms.  
Quantification of pharmacokinetic parameters is affected by field inhomogeneities, 
gradients, SNR of the reconstructed images, and spatiotemporal resolution [1].  Besides 
limitations in acquisition, quantification of pharmacokinetic parameters will depend on the 
selection of pharmacokinetic model, the accurate estimation of the arterial input function, the 
estimation of the native T1 of the tissue [2] and the selection of fitting algorithm. Heyes et al 
[[3], [4]] studied the variation within- and between workstations in the derivation of 
pharmacokinetic parameters and reported a 25.1%–74.1% within-subject coefficient of 
variation. The conclusion of these studies is that unless the contrast agent material, the 
definition of AIF, the image SNR, and the fitting process are standardized DCE MRI related 
parameters will not be reproducible.  Pharmacokinetic models such as the extended Toft model 
[5] that describe the enhancement process are often used to derive quantitative parameters and 
are increasingly used in diagnostic models [6] including computer aided diagnostic (CAD) 
software [[7], [8]]. Accurate quantification that will be reproducible between different clinical 
sites is necessary for the widespread of DCE based CAD software. This work will investigate 
how the optimization process itself can affect the quantification and the diagnostic ability of the 
quantified parameters.. 
Quantitative DCE parameters are usually extracted by fitting the estimated 
concentration to the measured concentration time course, using algorithms such as non-linear 
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least squares or the simplex algorithm. These fitting algorithms are prone to hit local minima [9] 
resulting in fitting errors and fitted parameters that depend on their initialization. To the best of 
our knowledge there are no guidelines on how to initialize the pharmacokinetics, and its clinical 
site uses its own initialization settings. Consequently there is a clear need to develop robust 
fitting strategies that will not be affected by the initialization of the pharmacokinetics.  
To overcome these issues, Bayesian inference algorithms were suggested [[10], [11], 
[12]]. Bayesian inference algorithms can model the noise of the measured concentration of the 
contrast agent and have a theoretical guarantee to converge if run long enough [13]. This work 
suggests a Bayesian inference algorithm similar to the ones proposed by other groups [[10], 
[11], [12]] and evaluates its robustness and diagnostic value against the Levenberg–Marquardt 
and the simplex algorithms on two separate cohorts of patients: 
i) a cohort of 76 men, 20 of whom had significant prostate cancer in the peripheral zone 
ii) a cohort of 9 healthy volunteers and 24 patients with squamous cell carcinoma. 
The proposed Bayesian inference algorithm is described in the theory section. The 
robustness value is assessed based on goodness-of-fit, and how robust the algorithm is when 
using different initialization settings of the estimated pharmacokinetic parameters. Receiver 
operating characteristic (ROC) analysis is performed on the derived pharmacokinetics to assess 
their ability to classify significant cancer.    
 
2. Theory 
2.1 Pharmacokinetic Modeling 
A pharmacokinetic analysis was performed by fitting the extended Toft [5] (Eq. 1) modelled 
concentration 𝐶(t)  (mmol/L) to the concentration time course 𝐶𝑇𝐼𝐶(t)   (Eq. 2). 
 
𝐶(t) = 𝑣𝑝 ∙ 𝐶𝑎(t) + 𝐾𝑡𝑟𝑎𝑛𝑠 ⋅ ∫ 𝐶𝑎(τ − 𝑡0) ⊗ e
(−
𝐾𝑡𝑟𝑎𝑛𝑠
𝑣𝑒
∙(𝑡−τ))
dτ
t
0
 (1) 
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Where 𝐶𝑎(t) is the arterial input function (mmol/L), 𝑣𝑝is the blood plasma volume fraction, 
𝐾𝑡𝑟𝑎𝑛𝑠is the transfer constant between plasma and interstitial space (min
-1),𝑣𝑒is the interstitial 
space volume and 𝑡0is the arrival time of the bolus at the tissue (secs). Population arterial input 
function was used [15]. 
The concentration time course was calculated from the image signal intensities 𝑆(t) using the 
approximation Repetition time⪡T1 
 
𝐶𝑇𝐼𝐶(t) =
1
𝑟1 ∙ 𝑇10 
(
𝑆(t) − 𝑆0
𝑆0
) (2) 
 
Where 𝑟1 is the in-vivo relaxivity (4.51 L mmol
-1 sec-1), 𝑇10 is the native T1 of the tissue 
before contrast agent injection, calculated from a multiple ﬂip angle dataset (sec), and 𝑆0 is the 
average of the acquired images before the injection of the contrast agent. 
 
2.2 Non linear regression algorithms 
Pharmacokinetic models are fitted with two commonly used non-linear regression algorithms 
i.e. the Levenberg-Marquardt and the simplex algorithm. Levenberg-Marquardt is a least squares 
curve fitting algorithm that is a blend between the Gauss–Newton and the gradient descent 
method. The update rule of the pharmacokinetics parameters is: ki+1=ki-(H+λI)-1∇L(ki), where H 
is the Hessian matrix at ki, λ is a regularization parameter and L is the likelihood function to be 
minimized i.e. L(ki)=∑ (𝐶𝑇𝐼𝐶(t) − 𝐶(t))
2
𝑡  . When the likelihood is decreased λ is also reduced, 
but if the likelihood is increased λ will also be increased to reduce the influence of gradient 
descent. Contrary to other gradient based methods Levenberg-Marquardt is not performing a 
line minimization (where the direction of gradient descent is decided prior to step size 
estimation) hence requires less likelihood evaluations reducing the computational cost.  
The simplex algorithm is also an iterative procedure but unlike the Levenberg-Marquardt 
does not require derivative information. The algorithm will create a “random” simplex of n+1 
points, where n is the number dimensions (number of pharmacokinetic parameters to be 
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estimated). The simplex moves iteratively by reflection, expansion or contraction steps trying to 
find the pharmacokinetic parameters that minimize the likelihood function. In this work we used 
a constrained variation of the simplex algorithm [[16],[17]] and an ℓ1-norm in the likelihood 
function to improve robustness [18]. Simplex algorithm is particularly advantageous in cases 
where the gradient of the likelihood functions is hard to calculate. 
 
2.3 Bayesian inference algorithm 
In the proposed Bayesian Inference algorithm the measured concentration 𝐶𝑇𝐼𝐶(t) is 
modelled using additive Gaussian noise σ and the  pharmacokinetic parameters, k= {vp, Ktrans, 
ve, t0} for the extended Tofts model or k= { γ,  Ktrans, ve, t0} for the Orton model 
 𝐶𝑇𝐼𝐶(t)~𝐧𝐨𝐫𝐦𝐚𝐥(𝐶(t), σ)   (3) 
The suggested Bayesian inference algorithm similar to [[10], [11], [12]] maximizes the posterior 
probability distribution function p(k,σ|CTIC) as a function of k and σ 
 ?̂?, ?̂? = 𝑎𝑟𝑔𝑚𝑎𝑥𝑘,𝜎  𝑝(𝑘, 𝜎|𝐶𝑇𝐼𝐶)  (4) 
According to the Bayes theorem p(k,σ|CTIC) is given by, 
 
𝑝(𝑘, 𝜎|𝐶𝑇𝐼𝐶) = 𝑝(𝑘, 𝜎) ∙ 𝑝(𝐶𝑇𝐼𝐶|𝑘, 𝜎) ∫ 𝑝(𝑘
∗, 𝜎∗) ∙ 𝑝(𝐶𝑇𝐼𝐶|𝑘
∗, 𝜎∗)
𝑘∗,𝜎∗
  (5) 
Where p(CTIC|k,σ) is the likelihood function of CTIC given the pharmacokinetic parameters k,  
 
𝑝(𝐶𝑇𝐼𝐶|𝑘, 𝜎) = (2𝜋𝜎
2)−1exp (−
1
2𝜎2
‖𝐶𝑇𝐼𝐶(𝒓, 𝑡) − 𝐶(𝒓, 𝑡)‖2
2)  (7) 
and p(k,σ) is the product of the prior probability distribution functions of k and σ, 𝑝(k, σ). 
Prior probability distribution functions reflect our prior knowledge about the k and σ 
parameters. We assume the subsequent prior distributions for every pharmacokinetic parameter 
 vp follows a Beta distribution, vp~Beta(1,19) [19] reflecting an a priori expected value 
of 0.05. 
 Ktrans was parameterized as suggested by Schmid et al [10] as eθ where θ follows a 
Gaussian distribution θ~Normal(0,1) 
 ve  follows a Beta distribution, ve~ Beta (2,1.5) reflecting an a priori expected value of 
0.57 
 t0 follows a random distribution.  
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 σ2 follows an uninformative Inverse Gamma distribution IG(10-4, 10-4)  
The integral ∫ 𝑝(𝑘∗, 𝜎∗) ∙ 𝑝(𝑦|𝑘∗, 𝜎∗)𝑘∗,𝜎∗  is estimated with the Metropolis–Hastings algorithm.  
 
3. Materials and methods 
3.1 Generate Simulated DCE data 
 The DCE simulation used is similar to the one published from our group in Dikaios et al 
(2014) [20]. A normal volunteer underwent a fast gradient echo DCE-MRI protocol (flip angle 
α=10o, repetition time TR=2.3 msecs). A T1-weighted abdominal image was acquired without 
contrast injection. The first time-frame was manually segmented into: liver, bowel, right and left 
heart, aorta, portal vein. Such segmentation was used as a map to simulate contrast enhancement 
using the extended Tofts model or the dual input function Orton model for the liver. Ground 
truth parametric maps i.e. native T10 (range 382-1932 msecs), vp (range 0-1), ve (range 0-1), 
and Ktrans  (range 0-1.38 min-1) were used to simulate fifty DCE images with temporal resolution 
3 secs using the spoiled gradient echo model.  
 
𝑆(𝑡) = 𝜌
sin(𝛼) ∙ (1 − exp (−
𝑇𝑅
𝑇1(𝑡; 𝑘)
))
1 − cos (𝛼) ∙ exp (−
𝑇𝑅
𝑇1(𝑡; 𝑘)
)
  (8) 
Where  is the proton density image, and was calculated analytically using Eq. 8 from the T1-
weighted abdominal image without contrast injection and the graund truth T10 maps.  
DCE images were transformed to (k, t)-space with fast Fourier transformation where noise was 
added. The noise of complex valued (k, t)-space MR data can be reasonably modelled by an 
additive white Gaussian distribution on both real and imaginary components (independent and 
identically distributed random variables). Simulated DCE data were generated for 2 different 
noise levels , one corresponding to the average SNR before contrast injection of prostate T1w  
images (SNR~9.2, noise level=2500) and a separate one corresponding to the average SNR 
before contrast injection of neck T1w images (SNR~15.1, noise level=800). The SNRs were 
calculated as described in Dikaios et al [21]. 
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3.2 Patient populations 
Institutional review board (IRB) approval for the study was obtained. The requirement 
for consent was waived for use of images acquired in routine clinical practice (prostate 
peripheral zone population) and obtained from all patients undergoing imaging as part of a 
separate clinical trial (head and neck population). 
 
Prostate population 
The prostate population consisted of men with clinically suspected prostate cancer (elevated 
prostate specific antigen (PSA) ± abnormal digital rectal examination ± family history of 
prostate cancer ± urinary symptoms,) undergoing prostatic multiparametric MRI (mp-MRI: T2 
weighted, diffusion weighted and DCE imaging) prior to template-prostate-mapping (TPM) 
biopsies as part of standard of care at our institution. In total 76 men (mean age 63 years, range 
45-79) with a mean prostate specific antigen of 7.8 ng/ml (range 1.2-20 ng/ml) and a mean 
prostate gland volume of 48.2 ml (range 23-137 ml) were included from 06/2007 to 03/2011. 
Twenty of the 76 men had histologically verified clinically significant peripheral zone prostate 
cancer. 
Imaging was performed using a 1.5T magnet (Avanto, Siemens, Erlangen, Germany) 
with a pelvic phased array coil. The contrast media was Dotarem with an application dose 0.2 
mL/Kgr.  Prior to imaging, 0.2 mg/kg (maximum 20 mg) of spasmolytic (Buscopan; Boehringer 
Ingelheim, Ingelheim, Germany) was administered intravenously to reduce peristalsis. DCE-
MRI was performed with a T1 weighted volumetric FLASH sequence with TR/TE 5.61/2.5 ms, 
flip angle 15o, 384384 matrix dimensions, field of view 269 mm, slice thickness 3 mm, 26 
reconstructed slices, temporal resolution of 16 seconds, and number of time points 35.  
For the purpose of this study and to match with the target performance of mp-MRI as defined by 
recent consensus [24]; histopathologists identified all locations with clinically significant cancer 
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based on volume assessment (0.2 ml) estimated by the cancer core length (CCL)>= 4 mm 
and/or the presence of Gleason pattern 4 disease [25]. Small volume (<0.2 ml) and low grade 
(<=Gleason 3+3) tumour was identified as clinically insignificant cancer.  
An experienced radiologist (with 10 years of mp-MRI experience, reporting 500 mp-
MRI prostate scans/year) and using the TPM biopsy histology as a guide, carefully matched the 
histopathology template to the mp-MRI; and contoured a region of interest (ROI) on early 
contrast enhanced T1 weighted images at the single largest histologically confirmed significant 
cancer site. For patients where the entire prostate was benign or contained only insignificant 
cancer, the radiologist contoured a 1-cm2 ROI at a confirmed benign location within the PZ. 
 
Head and Neck population 
Twenty-four consecutive patients (mean age 60 years, standard deviation 9 years, range 44 to 80 
years) satisfying inclusion criteria of histologically confirmed head and neck SCC with cervical 
nodal metastatic disease at pre-therapy staging, and 9 normal volunteers (mean age 48 years, 
standard deviation 16 years, range 20 to 75 years) were recruited between March 2010 and May 
2012. All patients underwent contrast enhanced neck computed tomography (CECT), 
anatomical MRI and neck ultrasound as part of routine pre-treatment staging; and were 
consented for additional DCE MRI of the neck for research purposes.  
All MRI studies were acquired using a 1.5T Siemens Avanto (Siemens, Erlangen, Germany) 
magnet with the manufacturer’s carotid coils. The contrast media was Dotarem with an 
application dose 0.2 mL/Kgr. DCE-MRI was performed with a T1 weighted volumetric FLASH 
sequence with TR/TE 2.3/1.0 ms, flip angle 10o, 256256 matrix dimensions, field of view 269 
mm, slice thickness 4 mm, temporal resolution of 3 seconds, and number of time points 50.  
The reference standard was established by experienced head and neck radiologists (with 8 years 
and 24 years of head and neck experience respectively) through review of all CT and anatomical 
MRI, and performance of ultrasound evaluation of the neck in all patients. Cervical nodes were 
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assessed as per the Union for International Cancer Control (UICC): Tumor nodal-metastasis 
(TNM) classification of malignant tumours [26]. Equivocal nodes were sampled at the time of 
ultrasound by fine needle aspiration (FNA) and classified by in-room cytology.  
 
3.3 Optimization details of the fitting algorithms 
Fitting algorithms were implemented with in-house–developed software in MATLAB 
(The Mathworks Inc, Natick, MA). The pharmacokinetic parameters for the simplex, the 
Levenberg-Marquardt and the Bayesian inference algorithm were initialized as vp0= 0.05, 
Ktrans0= 0.4 min-1, ve0= 0.5 for both the simplex and the Levenberg-Marquardt. The constraints of 
the pharmacokinetic parameters were: 𝑣𝑝 ∈ [0,1], 𝐾𝑡𝑟𝑎𝑛𝑠 ∈ [0,2.7] 𝑚𝑖𝑛
−1, 𝑣𝑒 ∈ [0,1], 𝑡0 ∈
[𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒, 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 + 40 𝑠𝑒𝑐𝑠]. Onset time was initialized with the time point the 
contrast agent was administered. 
The simplex, the Levenberg-Marquardt and the Bayesian inference algorithms were run 
using multiple initialisations of the pharmacokinetic parameters. In addition to the 
aforementioned initialization, 49 different initialisations were also generated (50 initializations 
in total) using uniform distributions supported within intervals as described by the following 
formulas: vp0= unif (0, 0.2), Ktrans0= unif (0.3, 1.0), ve0= unif (0.3, 0.6). 
For the proposed Bayesian inference algorithm the total number of iterations was 500, 
burn-in iterations were 300, thinning equal to 5, and tune iteration (number of iterations for 
tuning) was 67. 
 
3.4 Statistical analysis 
Statistical analysis was performed using SPSS (SPSS Base 20.0 for Windows. SPSS 
Inc., Chicago IL). The same statistical analysis was performed for both the head and neck and 
PZ prostate population. 
A Mann–Whitney U test (MWU sig) was performed to compare the median values of 
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the pharmacokinetic parameters between normal and cancer ROIs. The goodness-of-fits of the 
simplex, Levenberg-Marquardt and the Bayesian inference algorithms were assessed with the 
Kolmogorov-Smirnov (KS) test statistic. 
Separate univariate logistic regression models were built for the pharmacokinetic 
parameters derived using the simplex and the Bayesian inference algorithms. The ability of 
individual pharmacokinetic parameters to classify cancer was assessed by receiver operator 
characteristic (ROC) area under curve (AUC) analysis.  
Leave-one-out analysis [21] was used for internal validation of predictive models. One 
case (out of the total patient population) was excluded, and a model generated from the 
remainder of the cases. The model was then tested on the excluded case and a predictive 
probability calculated. The process was repeated for all cases, excluding successive cases in turn 
allowing calculation of a predictive probability per case. An ROC (LOO ROC) was then created 
using the derived predictive probabilities. ROC curves were compared using the significance 
test suggested by Hanley and McNeil [27]. 
 
4. Results 
4.1 Simulated DCE data 
Table 1 demonstrates the similarity in terms of Structural SIMilarity (SSIM) index of 
the estimated pharmacokinetic maps estimated with the simplex, the Levenberg Marquardt and 
the Bayesian algorithm to the ground truth pharmacokinetic maps. Results are shown for two 
different noise realizations, one corresponding to the SNR of prostate T1w images (~9.2) before 
contrast injection and one corresponding to the SNR of neck T1w images (~15) before contrast 
injection. The pharmacokinetic maps estimated with the Bayesian algorithm have substantially 
higher SSIM and are less affected from the different initializations of the pharmacokinetic 
parameters (lower interquartile range across the 50 different initializations). The simplex 
algorithm has similar performance to the Levenberg-Marquardt (LM), with marginally higher 
 13 
SSIM. Fig. 1 provides a visual comparison between the pharmacokinetics maps estimated with 
the simplex and the Bayesian algorithm. 
 
 
Fig. 1  
Parametric maps (vp, Ktrans, ve, t0) estimated with pixel-by-pixel fitting of the simulated DCE 
images with SNR=9.2 using the simplex and the Bayesian inference algorithms. Ground truth 
pharmacokinetics maps are shown at the top row. 
 
Table 1  
SIMilarity (SSIM) index between the parametric maps (vp, Ktrans, ve, t0) estimated with pixel-by-
pixel fitting (using the simplex, the Levenberg Marquardt and the Bayesian inference algorithms) 
and the ground truth parametric maps of simulated DCE data. Results are shown for different 
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noise realizations with SNR=9.2 (prostate T1w images) and SNR=15 (neck T1w images). Median 
and Interquartile range (iQR) of SSIM were calculated across the 50 different initializations for 
each method. 
 Median (iQR) vp Ktrans  ve t0 
SNR=9.2 
simplex 0.90 (0.17) 0.69 (0.13) 0.81 (0.14) 0.70 (0.12) 
LM 0.89 (0.17) 0.69 (0.14) 0.80 (0.15) 0.68 (0.14) 
Bayesian 0.92 (0.02) 0.81 (0.01) 0.84 (0.02) 0.76 (0.01) 
SNR=15 
simplex 0.95 (0.11) 0.81 (0.10) 0.87 (0.08) 0.79 (0.09) 
LM 0.95 (0.11) 0.81 (0.10) 0.86 (0.08) 0.79 (0.09) 
Bayesian 0.98 (<0.01) 0.91 (<0.01) 0.93 (0.01) 0.86 (0.01) 
 
 
4.2 Prostate population  
Multiple initialisations – Robustness of evaluated algorithms 
The simplex, the Levenberg-Marquardt and the Bayesian inference algorithms were all run with 
the same 50 different initializations, Fig. 2 shows the KS test statistic (across the 76 mean ROI 
profiles of the PZ prostate population) for each initialization. The interquartile range of the 
medians was 0.019 for the simplex algorithm, 0.018 for the Levenberg-Marquardt algorithm and 
0.002 for the Bayesian inference algorithm. Simplex algorithm had consistently better 
goodness-of-fit than the Levenberg-Marquardt; hence hereafter the Levenberg-Marquardt was 
excluded from the comparison. 
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Fig. 2 
Plot of the median KS statistic test (median KS statistic test across the 76 mean ROI PZ prostate 
profiles) across the 50 different initializations for the Levenberg-Marquardt, the simplex and the 
Bayesian inference algorithms. The interquartile range (iQR) of the median KS statistic test is 
0.019 for the Levenberg-Marquardt, 0.018 for the simplex and 0.002 for the Bayesian inference 
algorithm.  
 
Univariate ROC analysis 
Table 2 shows the ROC analysis of the pharmacokinetic parameters estimated with the simplex 
and the Bayesian inference algorithms using the optimum pharmacokinetic initialization in 
terms of goodness-of-fit.  Ktrans was the best classifier of PZ prostate cancer for both the simplex 
and the Bayesian inference algorithm. According to the score test only Ktrans estimated with the 
Bayesian inference algorithm could significantly discriminate PZ prostate cancer (p=0.02) 
(Table 2). However following a significance test between ROC curves, the AUC of Ktrans 
estimated with the Bayesian inference algorithm (shown in Table 2) was not significantly better.  
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The simplex and the Bayesian inference algorithms were run with different 
initializations as described in section 3.3 and the ROC AUC were estimated per 
pharmacokinetic parameter for each initialization. The median (interquartile range) ROC AUC 
across the 50 different initializations were vp:0.55 (0.05), Ktrans:0.57 (0.14), and ve:0.56 (0.05) 
for the simplex algorithm and vp:0.63 (0.02), Ktrans:0.67 (0.02), and ve:0.56 (0.01) for the 
Bayesian algorithm. The median ROC AUC values for vp and Ktrans between the simplex and the 
Bayesian were significantly different. 
 
Table 2 
Score test and univariate ROC analysis of the pharmacokinetic parameters derived with the 
simplex and the Bayesian inference algorithms (using the optimum pharmacokinetic initialization 
in terms of goodness-of-fit) performed on the whole PZ population and following LOO analysis. 
 
 
 
 
 
 
 
Comparison of pharmacokinetic parameters between PZ prostate cancer/benign ROIs 
Parametric maps of a PZ prostate cancer patient estimated with the simplex and the Bayesian 
inference algorithms are illustrated in Fig. 3. The modelled concentration C(t) is fitted to the 
mean concentration profile along the PZ prostate cancer ROI CTIC(t) (Fig. 3).  In Fig. 3, while vp 
values estimated from the cancer ROI profile are almost zero for the simplex algorithm, 
following pixel-by-pixel fitting the cancer area in the vp seems to be slightly higher than zero. 
Pharmacokinetic parameters estimated by fitting mean ROI profiles will not necessarily 
correlate with pharmacokinetic parameters estimated by pixel-by-pixel fitting. Taking the mean 
    score (p-value) ROC AUC (CI) LOO ROC AUC (CI) 
simplex 
vp 0.21 (0.65) 0.61 (0.47-0.76) 0.22 (0.11-0.33) 
Ktrans 3.22 (0.07) 0.64 (0.50-0.78) 0.57 (0.41-0.72) 
ve 0.69 (0.41) 0.54 (0.40-0.68) 0.41 (0.28-0.54) 
 
 
  
 
Bayesian 
vp 2.31 (0.13) 0.58 (0.43-0.74) 0.48 (0.32-0.65) 
Ktrans 5.46 (0.02) 0.67 (0.54-0.81) 0.63 (0.50-0.77) 
ve 0.75 (0.39) 0.56 (0.41-0.71) 0.44 (0.30-0.58) 
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of an ROI and propagating it in time will generate a “smooth” profile, resulting in an 
approximated time-intensity curve. Ideally pixel-by-pixel fitting needs to be performed, but 
because it is more computationally demanding many clinical papers resort to mean ROI profile 
fitting. 
Following MWU test, none of the pharmacokinetic parameters estimated with the Bayesian 
inference algorithm were significantly different from the ones estimated with the simplex 
algorithm for either the benign or the cancer ROIs (Fig. 4). 
Fig. 3 
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Pharmacokinetic maps (vp, Ktrans, ve) estimated with pixel-by-pixel fitting using the simplex and 
the Bayesian inference algorithms for a PZ prostate cancer patient. A plot of the mean ROI 
concentration profile 𝐶𝑇𝐼𝐶(t) and the fitted to curve using the simplex and the Bayesian inference 
algorithms is also shown.  
 
Fig. 4  
Boxplot diagram of the pharmacokinetic parameters derived with the simplex and the proposed 
Bayesian inference algorithm, performed separately for the normal and cancer PZ prostate ROIs. 
The terms in brackets refer to the median value (interquartile range) of the estimated 
pharmacokinetic parameters.  
 
4.3 Head and Neck population    
Multiple initialisations – Robustness of evaluated algorithms 
The simplex, the Levenberg-Marquardt and the Bayesian inference algorithms were all 
run with the same 50 different initializations, Fig. 5 shows the median KS statistic test (across the 
33 mean ROI profiles of the head and neck patients and volunteers) for each initialization. The 
interquartile range of the medians was 0.0083 for the simplex algorithm, 0.010 for the Levenberg-
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Marquardt algorithm and 0.0021 for the Bayesian inference algorithm. Simplex algorithm had 
consistently better goodness-of-fit than the Levenberg-Marquardt; hence from hereafter the 
Levenberg-Marquardt was excluded from the comparison. 
 
 
Fig. 5  
Plot of the median KS statistic test (median KS statistic test across the 33 mean ROI head and 
neck profiles) across the 50 different initializations for the simplex and the Bayesian inference 
algorithms. The interquartile range (iQR) of the median KS statistic test is 0.010 for the 
Levenberg-Marquardt, 0.0083 for the simplex and 0.0021 for the Bayesian inference algorithm.  
 
Univariate ROC analysis 
Table 3 shows the ROC analysis of the pharmacokinetic parameters estimated with the 
simplex and the Bayesian inference algorithms using the optimum pharmacokinetic initialization 
in terms of goodness-of-fit.  Ktrans was the best classifier of head and neck metastatic patients for 
both the simplex and the Bayesian inference algorithms. According to the score test, for the 
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simplex algorithm only Ktrans could significantly classify metastatic patients, whereas for the 
Bayesian inference both Ktrans and ve were significant classifiers (table 3). 
Following a significance test between ROC curves, the AUC (on the original population or 
following LOO analysis) of Ktrans, estimated with the Bayesian inference algorithm, was not 
significantly better. Significant difference was only found for the ve AUC between the simplex 
and the Bayesian inference algorithms (table 3).  
The simplex and the Bayesian inference algorithms were run with different initializations 
as described in section 3.3 and the ROC AUC were estimated per pharmacokinetic parameter for 
each initialization. ROC AUC were estimated per pharmacokinetic parameter for each 
initialization. The median (interquartile range) ROC AUC across the 50 different initializations 
were vp: 0.54 (0.14), Ktrans:0.76 (0.13), and ve:0.56 (0.15) for the simplex algorithm and vp:0.59 
(0.03), Ktrans:0.81 (0.01), and ve:0.79 (0.02) for the Bayesian algorithm. The median ROC AUC 
values for ve between the simplex and the Bayesian were significantly different. 
 
Table 3  
Score test and univariate ROC analysis of the pharmacokinetic parameters derived with the 
simplex and the Bayesian inference algorithms (using the optimum pharmacokinetic initialization 
in terms of goodness-of-fit) performed on the whole head and neck patient population and 
following LOO analysis. Asterisk (*) denotes the cases where the pharmacokinetic parameter 
estimated with the Bayesian inference algorithm is significantly different from the corresponding 
one derived with the simplex algorithm. 
    score (p-value) ROC AUC (CI) LOO ROC AUC (CI) 
simplex 
vp 0.12 (0.73) 0.56 (0.33-0.79) 0.30 (0.13-0.48) 
Ktrans 5.43 (0.02) 0.74 (0.58-0.90) 0.66 (0.43-0.89) 
ve* 0.54 (0.49) 0.56 (0.34-0.77) 0.31 (0.15-0.50) 
 
 
   
Bayesian 
vp 1.05 (0.31) 0.58 (0.35-0.80) 0.51 (0.31-0.72) 
Ktrans 6.37 (0.01) 0.80 (0.64-0.94) 0.75 (0.57-0.92) 
ve* 4.76 (0.03) 0.76 (0.60-0.93) 0.70 (0.52-0.89) 
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Comparison of pharmacokinetic parameters between metastatic/benign ROIs 
Parametric maps of a head and neck metastatic patient estimated with the simplex and the 
Bayesian inference algorithms are illustrated in Fig. 6. Fitting the estimated concentration C(t) to 
the mean ROI concentration profile along the head and neck metastatic nodes CTIC (t) is also 
shown in Fig. 6.   
Following MWU test all the pharmacokinetic parameters estimated with the Bayesian 
inference algorithm were significantly different from the ones estimated with the simplex 
algorithm for both the benign and the cancer ROIs (Fig. 7). 
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Fig. 6  
Parametric pharmacokinetic maps (vp, Ktrans, ve) estimated with pixel-by-pixel fitting using the 
simplex and the Bayesian inference algorithms for a head and neck patient with a metastasis. A 
plot of the mean ROI concentration profile 𝐶𝑇𝐼𝐶(t) and the fitted curve using the simplex and 
the Bayesian inference algorithms is also shown. 
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Fig. 7 
Box-plot diagram of the pharmacokinetic parameters derived with the simplex and the proposed 
Bayesian inference algorithms, performed separately for the benign and metastatic neck node 
ROIs. The terms in brackets refer to the median value (interquartile range) of the estimated 
pharmacokinetic parameters. Asterisk (*) denotes significant difference (p<0.05) between the 
simplex and Bayesian inference algorithms.  
 
5. Discussion 
This works aims to investigate the diagnostic benefits of using Bayesian Inference 
algorithms for the derivation of pharmacokinetic parameters in DCE-MRI. The proposed 
Bayesian Inference algorithm is compared against non-linear regression algorithms (i.e. 
Levenberg-Marquardt and simplex) in terms of accuracy, reproducibility under different 
initialization settings and ability to classify cancer.  
The simplex algorithm had consistently marginally higher SSIM with the ground truth 
kinetics of the simulated DCE phantom and better goodness-of-fit for the ROI-based TIC of both 
 24 
populations than the Levenberg–Marquardt, which could be attributed to its convergence 
properties [17]. Unlike the Levenberg–Marquardt, the simplex algorithm does not use gradients, 
which provides some resilience to noise and local minima.   
When running the proposed Bayesian inference algorithms for different initializations we 
found that 
i. The SSIM with the ground truth pharmacokinetic maps for the Bayesian inference 
algorithm was consistently higher than for the non-linear regression algorithms for all 
initializations. 
ii. The goodness-of-fit (KS statistic test) for the Bayesian inference algorithm was almost 
constant and consistently lower than the non-linear regression algorithms for all 
initializations and for both populations. 
iii. The ROC AUC of the pharmacokinetic parameters estimated with the Bayesian 
inference algorithms have an interquartile range across the different initializations up to 
0.03, whereas for the simplex algorithm the interquartile range is up to 0.14 (PZ prostate 
population) and 0.15 (head and neck population). 
Pharmacokinetic parameters estimated with the proposed Bayesian inference algorithm 
had higher classification ability for both PZ prostate and head and neck cancer. Pharmacokinetic 
parameters estimated with the simplex algorithm that could not significantly classify disease, 
when estimated with the proposed Bayesian inference algorithm were significant classifiers of PZ 
prostate cancer (i.e. Ktrans) and metastatic head and neck cancer (i.e. ve). However the ROC AUC 
improvement achieved with the Bayesian inference algorithm was not significant for the PZ 
prostate cancer. For the head and neck metastasis only the ROC AUC improvement for ve was 
significant. 
 
Bayesian inference algorithms have been proposed before in the literature [[10], [11], 
[12]] to estimate unbiased quantitative pharmacokinetic parameters. The proposed scheme is 
similar to the one suggested by Schmid et al [10], the main difference is on the estimation of the 
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onset time. The accuracy of the estimated pharmacokinetic parameters will depend on the arrival 
time of the contrast agent to the tissue (onset time) [28]. Schmidt et al [7] calculated the onset 
time as the minimum time t*, for which the contrast concentration significantly exceeds zero 
minus C(t*)/tC(t*). For the simulated DCE phantom with SNR=9.2, the SSIM index of the onset 
time calculated with the method of Schmidt et al [10] is 0.5754, whereas for the proposed 
Bayesian algorithm the respective SSIM is 0.76 (Table 1). This affected the estimation of the 
pharmacokinetic parameters, but if the same onset time was used the Bayesian method suggested 
by Schmid et al [10] has similar performance with the one proposed in this work. This is expected 
since both use the Metropolis–Hastings Markov chain Monte Carlo (MCMC) method and similar 
prior information. Their only difference is that we parameterized the posterior probability 
distribution function p(k,σ|CTIC) with ve to optimize EES volume directly instead of calculating it 
via kep (ve=Ktrans/kep) [7]. 
 
6. Limitations 
For the PZ prostate population, we were reliant upon visual matching of the Barzell zone histology 
on TPM with the ROIs on the mp-MRI. Therefore, results may be influenced by mis-registration 
errors. Although no biopsy is free from sampling error [29] we used TPM to address as much of 
the systematic error inherent to transrectal ultrasound (TRUS) guided biopsy as possible [[29], 
[30]].  For the head and neck population there was a relatively small sample size. We took great 
care to be certain about positive and negative disease status within individual nodes by recruiting 
patients with N2/3 disease confirmed by CT, MRI and US ± FNA.  
 
7. Conclusions  
DCE MRI pharmacokinetic parameters are increasingly used in clinical practice; their diagnostic 
ability will depend on their accurate and reproducible quantification.  The proposed Bayesian 
inference algorithm has been shown in this work to improve the diagnostic ability compared to 
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the simplex algorithm and was robust when different initializations of the pharmacokinetic 
parameters were used. These assets of the algorithm are essential to train and validate robust CAD 
software based on DCE-MRI that could be used between different sites. The performance of the 
Bayesian inference algorithm was consistent on two different populations, acquired with different 
settings. 
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